Its first-quarter profit stood at RON7.13 million, up 17% from RON6.06 million in the same period in 2015.
Antibiotice Iasi said in a report submitted to the Bucharest Stock Exchange that it continued its consolidation on the Romanian pharmaceutical market.
According to an analysis by market research company Cegedim, in January-March 2016, the company registered increases on the segment of over-the-counter drugs whose weight in overall sales reached approximately 15%.
Antibiotice is majority-owned by Romania’s Health Ministry, with a 53.02% stake, while regional investment fund SIF Oltenia (SIF5. RO) holds a 10.1% stake.